Detection of hematogenous micrometastasis in patients with prostate cancer.
Publication/Presentation Date
11-1-1992
Abstract
The goal of this study was to determine if patients with stage D0-3 prostatic adenocarcinoma have detectable hematogenous micrometastasis. Polymerase chain reaction amplification of prostate-specific antigen mRNA, which is exclusively expressed by prostatic epithelial cells, was used to detect circulating prostatic cells. Peripheral venous blood was obtained from 17 control and 12 prostate cancer patients with stage D0-3 prostatic adenocarcinoma. Of the 12 cancer cases, four patients (stage D1-3) tested positive for prostate-specific antigen RNA, indicating the presence of circulating micrometastasis. The 17 negative controls all tested negative. Contrary to a long held hypothesis, these data point to the possibility that hematogenous metastasis may be a relatively early event in the natural history of human prostate cancer. These findings may have an important impact on our understanding and treatment of prostate cancer.
Volume
52
Issue
21
First Page
6110
Last Page
6112
ISSN
0008-5472
Published In/Presented At
Moreno, J. G., Croce, C. M., Fischer, R., Monne, M., Vihko, P., Mulholland, S. G., & Gomella, L. G. (1992). Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer research, 52(21), 6110–6112.
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
1382851
Department(s)
Administration and Leadership
Document Type
Article